Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2 inhibitors as a potential treatment strategy for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Hata, Aaron N, Rowley, Steve, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Ji, Fei, Jung, Joonil, Light, Madelyn, Lee, Joon Sang, Debussche, Laurent, Sidhu, Sukhvinder, Sadreyev, Ruslan I, Watters, James, Engelman, Jeffrey A
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700857/
https://ncbi.nlm.nih.gov/pubmed/28783173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.258
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados